INDICATION
Indications
  • KYPROLIS® (carfilzomib) is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone or with daratumumab and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
  • KYPROLIS® is indicated as a single agent for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.
  • ... Read More 
FDA APPROVED
KYPROLIS®+Darzalex® (daratumumab)+dexamethasone
LEARN MORE
X
Cookies help us improve your website experience.
By using our website, you agree to our use of cookies.
Confirm